How are you doing today, everyone? This morning, cloudy skies are hovering over the Pharmalot campus, where things have settled down since the short person has departed for a higher education institution and the official mascots have assumed their designated sleeping positions.
As we prepare for yet another hectic day, we are diligently brewing a few much-needed cups of stimulation. Certainly, you can empathize.
Today’s selection is toasted coconut. Thus, it is time to get started. As usual, we have compiled some interesting articles. So raise your own glass to a productive day and send us a line when something intriguing occurs…
STAT reports that patients across the United States are preparing for “D-Day,” the date their insurance companies will cease covering weight loss drugs. Insurance investigators are sending letters to physicians discouraging new prescriptions. In addition, insurers instruct pharmacies to look for a specific diagnosis before filling prescriptions.
The measures are part of a comprehensive endeavor by insurers to rein in rising costs. These off-label prescriptions were covered without issue for some time.
This year, however, insurers have begun clamping down aggressively on the medications, which have a monthly list price of at least $900 and are intended to be taken indefinitely.
NBC News reports that a woman from Louisiana has filed a lawsuit alleging that Novo Nordisk and Eli Lilly neglected to adequately warn patients about the potential risk of severe stomach problems associated with their medications Ozempic and Mounjaro.
The lawsuit filed by Jacklyn Bjorkland, who claims she was “severely injured” after taking two diabetes medications, is the first to assert that the medications can cause gastrointestinal injuries.
The lawsuit alleged that the drug manufacturers neglected to disclose other alleged side effects, including severe gastroparesis, also known as stomach paralysis, and “persistent” vomiting.